Drugs / TOL101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01154387 | Jul 2010 → Jun 2013 | end stage renal failure | Tolera Therapeutics, Inc | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TOL101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01154387 ↗ |
| Modality | Monoclonal antibody | “TOL101, an Anti-TCR Monoclonal Antibody” NCT01154387 ↗ |
| Route | Intravenous | “Potential Therapeutic Dose (PTD)-A (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant” NCT01154387 ↗ |